Heart failure
Conditions
Interventions
Sponsors
The First Affiliated Hospital of Wenzhou Medical University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Heart failure patient group (1) Meet the diagnostic criteria for heart failure: meet the 2021 ESC diagnostic guidelines for acute and chronic heart failure and the 2022 ACC/AHA phased criteria for heart failure, and meet the following two core conditions: 1) Evidence of structural/functional abnormalities: echocardiography showing left ventricular ejection fraction (LVEF) =50% with cardiac structural or functional abnormalities (HFpEF); 2) Biomarkers: NT-proBNP=125 pg/mL (non-acute phase) or BNP>=35 pg/mL; (2) Age 18-90 years; (3) Signed informed consent; 2. Non-heart failure control group (1) Age and gender matched with heart failure group (±5 years); (2) No history and symptoms of cardiovascular disease (chest pain, dyspnea, etc.); (3) the diagnosis of heart failure was excluded (NT-proBNP<100 pg/mL and no structural abnormalities were found on echocardiography); (4) Sign the informed consent form.
Exclusion criteria
Exclusion criteria: 1. Cancer or other serious comorbidities that affect life expectancy; 2. Systemic infection; 3. Liver dysfunction; 4. Pregnant or lactating women; 5. Mental disorder or cognitive deficit unable to cooperate with the study; 6. Combined with autoimmune diseases; 7. After enrollment, it was found that the inclusion criteria were not met (such as misdiagnosis of heart failure); 8. More than 20% of key data are missing (e.g., baseline biological sample collection has not been completed); 9. Serious violation of the protocol by the study intervention (such as unauthorized use of investigational drugs).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Cardiovascular death (sudden cardiac death, death from heart failure worsening);Rehospitalization for heart failure (requiring intravenous diuretic/inotropes); | — |
Secondary
| Measure | Time frame |
|---|---|
| All-cause mortality ;Unplanned revascularization;New myocardial infarction;New cerebrovascular accident;New-onset atrial fibrillation;Deterioration of renal function (decreased eGFR >=40%); | — |
Countries
China
Contacts
Public ContactHao Zhou
The First Affiliated Hospital of Wenzhou Medical University
Outcome results
None listed